What a pharmacy makes
A pharmacist, doctor, or registered medicine-making facility compounds a drug by preparing it instead of dispensing the maker’s finished version.
These batch-making facilities choose FDA registration; under the November 3, 2026 rules, this kind of place is called a 503B outsourcing facility. It is a physical place, not an online site.
FDA handles federal drug reviews. The position checked November 3, 2026 is clear: FDA approval does not extend to a compounded drug. Before those drugs reach the market, FDA has not tested their quality or reviewed their safety and benefit.
Ask what need this drug is meant to meet. Ask why an approved option would not meet that need. Put the answer beside the pharmacy’s name. The word custom does not tell you what was changed or why.
Keep the discussion about the drug separate from the price. A lower bill does not describe what a person is getting. Ask for each answer in words you can follow.
What the October draft says
The Department of Health and Human Services (HHS) wrote this draft, dated October 30, 2026. Its named ingredients are TB-500, semax, MOTS-c, KPV, BPC-157, and epitalon. Its terms are not binding.
In that draft, HHS says it does not plan enforcement action against a doctor or state-licensed pharmacy for making these drugs for an individual prescription, if every condition in the draft is met.
Only the listed preparations
Each drug must be for a named person’s prescription. Only a single ingredient is covered. Mixing ingredients into a blend takes it outside the draft. The registered batch-making facilities under section 503B are also excluded.
The draft also limits the forms of each ingredient and how the drug is given. The November 3, 2026 review confirms that it grants no FDA approval or right to compound.
Approval remains separate
Section 503A of federal law covers the pharmacy or doctor who prepares a prescribed medicine for an individual. This still requires meeting the law’s conditions, according to the November 3, 2026 check.
The November 3, 2026 check still finds none of those six peptides on the official 503A bulks list. A bulks list names raw drug ingredients; the 503A list adds ingredients beyond the law’s other ways for an ingredient to qualify. A withdrawn request does not meet the ingredient rules or give permission to compound.
Ask which part of the draft the proposed drug relies on. Ask how the pharmacy checks that it meets each term.
A vote is advice rather than a rule change
In its October 30, 2026 policy, HHS reports that FDA’s pharmacy-compounding advisory panel voted in July to support adding six of the seven peptides to the ingredient list. This is the official HHS account, not FDA meeting minutes.
As checked November 3, 2026, a panel vote does not change the list by itself. A list change needs a formal rule process with public comment.
On the FDA page marked as current on April 22, 2026, a separate table records ingredients whose supporters took back their requests to allow use in compounding. Beside those ingredients, the FDA retains warnings about possible harm. Taking back a request gives no approval or permission to compound. The page does not say when any individual request was withdrawn or when its listing changed.
The concerns include reactions by the body’s defenses to an injected peptide, impurities, and too little information about harm in people, according to the November 3, 2026 review.
A withdrawn request means the group that asked for the ingredient took that request back. The group’s decision is not FDA approval of the drug or permission to make it.
Ask which event a headline is talking about. A request, a vote, and a draft can each tell part of the story. Read the terms behind that event before drawing a conclusion.
The copying rule still needs an answer
Under the law checked November 3, 2026, an ordinary pharmacy faces limits on making copies of a sold drug as a routine or large-volume practice.
A prescriber’s finding of a significant change for a particular person belongs to a separate part of that rule.
Semaglutide and tirzepatide are off the national shortage list and absent from the 503B bulks list, as checked November 3, 2026. That bulks list names raw ingredients allowed for the registered batch-making facilities.
Use the FDA’s shortage and copy rules when asking about that proposal.
Ask the prescriber and pharmacy to put the basis for the drug in writing. Keep the answer with the quote and read both before deciding.